Introduction
The tumour suppressor p53 is believed to restrict neoplastic progression through the maintenance of genomic integrity . Inactivation of p53 in the germ-line of both experimental animals (Donehower et al., 1992) and in the human Li ± Fraumeni syndrome (Malkin et al., 1990; Srivstava et al., 1990) leads to a greatly increased predisposition to cancer in a range of tissues. Somatic mutations of the p53 gene occur in over 50% of human tumours (Greenblatt et al., 1994) , and commonly lead to the expression of a stable, yet inactive, protein that is readily detectable by immunohistochemical techniques. p53 protein overexpression has thus been used as the basis for a rapid screen for p53 abnormality in tumour specimens and may be an indicator of prognosis in some forms of neoplasia Dowell and Hall, 1995) . A complication of the interpretation of such studies, however, is the existence of a subset of human tumours which express high levels of p53 protein in the absence of any mutation in the p53 gene (Wynford-Thomas, 1992) , examples including a signi®cant proportion of breast tumours (Dunn et al., 1993; Macgeoch et al., 1993) , non small cell lung cancers (Carbone et al., 1994; Top et al., 1995) colorectal carcinomas (Cripps et al., 1994; Dix et al., 1994) and astrocytomas (Rubio et al., 1993; Lang et al., 1994) . Here we have used a cell line model to investigate the functional signi®cance of overexpressed wild-type p53 in transformed cells.
Normal, untransformed cells express low levels of inactive p53 which can be activated by DNA damage, for example u.v. irradiation, to acquire sequencespeci®c DNA binding (Tishler et al., 1993) and transcriptional activation properties (Lu and Lane, 1993; Hupp et al., 1995) . Depending on the agent and dose there may also be an increase in the stability, and hence levels of expression, of p53 protein (Maltzman and Czyzyk, 1984; Fritsche et al., 1993; Hupp et al., 1995) . The activation of transcription of p53-inducible genes such as WAF-1 (El-Deiry et al., 1993), GADD45 , mdm-2 and bax (Miyashita and Reed, 1995) plays a major role in the induction of cell cycle arrest and apoptosis by p53. This ability to activate transcription is lost by most tumour-derived p53 mutants , and is also inhibited by the products of viral oncogenes including SV40 T (Bargonetti et al., 1992) adenovirus E1B 55K (Yew and Berk, 1992) and HPV-16 E6 (Mietz et al., 1992) , as well as the cellular oncoprotein mdm-2 (Hoppe- Seyler and Butz, 1993; Wu et al., 1993) .
In our laboratory we have established an in vitro model of multi-step epithelial tumorigenesis initiated by infection of primary rat thyroid epithelial cells with a retroviral vector encoding mutant ras (Burns et al., 1992a; Blaydes et al., 1995) . Following a period of rapid cell proliferation the majority of ras infected colonies cease to divide. However a small proportion undergo a second, spontaneous immortalisation event which is invariably associated with a dramatic increase in the levels of p53 protein expression. We have established a panel of cell lines from these cells and have shown, by sequencing the entire p53 coding region, that the p53 protein is not mutated (Burns et al., 1992a; Blaydes et al., 1995) .
In this study we have examined p53 function and its regulation in a representative of these lines, PRT.ras.Vh1(Vh1), in comparison with a well char-acterised, non-transformed rat thyroid epithelial cell line, FRTL-5, in which low levels of wild-type p53 are expressed. Our primary aim was to determine whether the mechanism by which Vh1 cells tolerate high levels of wild-type p53 operates at the level of the p53 protein itself, or in a downstream signalling pathway. Our results show ®rstly that most of the`excess' p53 in Vh1 cells is inactive as a sequence-speci®c transcription factor, and secondly that this lack of p53 activity is, at least in part, dependent on the operation of the mdm-2 feedback loop.
Results
We considered three general mechanisms whereby Vh1 cells might tolerate high levels of p53 protein. (i) The protein itself may be fully functional but fails to exert a growth suppressive response due to a defect in a downstream eector pathway. For example loss of p21 WAF-1 function would be predicted to reduce the ability of p53 to induce growth arrest and indeed a partial loss of the g-irradiation induced G 1 /S checkpoint has been reported in ®broblasts from WAF-1 null mice (Deng et al., 1995) . (ii) The p53 protein itself may be inactive with respect to one or more of its proposed growth suppressive properties. This could be due either to a failure to correctly activate the protein by posttranslational modi®cation, or to a modi®cation which renders it inactivatable. (iii) The p53 may be in a potentially fully active form, but complexed with inhibitory cellular factors, an obvious candidate being mdm-2.
We initially set out to investigate the ®rst mechanism by determining whether the p53 in Vh1 cells is itself active, as assessed by its ability to activate transcription from a reporter construct, pRGCDfos-lacZ, containing a p53-responsive element upstream of the b-galactosidase gene. Given that transient transfection has itself been shown to induce p53 activity (Renzing and Lane, 1995) , we chose instead to stably co-transfect the reporter plasmid with a selectable marker, and subsequently compare b-galactosidase expression in clones of Vh1 and FRTL-5 cells matched for the amount of integrated reporter.
Selection of clones stably expressing a p53-dependent reporter construct
Both Vh1 and FRTL-5 cells were co-transfected, in three separate experiments, with pRGCDfos-lacZ and pSV 2 neo. Following G418 selection, colonies were picked, expanded, and those demonstrating DNA damage-inducible b-galactosidase expression identi®ed by X-gal enzyme histochemistry 17 h following exposure to 10 Jm 72 u.v. irradiation. (Preliminary experiments using pooled colonies stably transfected with the PG 13 -CAT or MG 15 -CAT reporter constructs had previously demonstrated that a u.v. response could be obtained). 13/75 Vh1.RGC.neo and 6/70 FRTL-5.RGC.neo clones demonstrated induction of b-galactosidase expression. Southern blotting was performed on DNA extracted from these clones to detect the bacterial b-galactosidase gene (not shown). Representative clones FRTL-5.RGC.neo-4 (FRn.4) and Vh1.RGC.neo-6 (VRn.6), containing equal amounts of the integrated plasmid (three copies), were selected for further study. Variations in b-galactosidase expression between these, and the other clones, correlated well with dierences in pRGCDfoslacZ copy number.
To demonstrate that the induction of b-galactosidase activity by u.v. was p53 dependent, we also transfected Vh1 cells with the pDfos-lacZ control vector lacking the p53 consensus site. No clones demonstrating u.v. inducible b-galactosidase expression were obtained. As a further control, Vh1 cells were also co-transfected with pRGCDfos-lacZ and pC53-SCX3, which encodes both neo and a temperature-sensitive p53, and clones showing temperature-dependent b-galactosidase expression isolated. Vh1.RGC.SCX-2 (VRs.2) was used as a representative clone.
The excess wild-type p53 in Vh1 cells does not result in increased levels of p53 dependent transcription Table 1 ) and the total bgalactosidase activity in cell extracts (Table 2) . We also observed, incidentally, that the b-galactosidase expression in VRn.6 cells showed a marked dependence on density, only *1% of cells stained positive by X-gal histochemistry at low density, compared to *10% in con¯uent cultures.
To con®rm that the b-galactosidase activity present in the 5 ± 10% of positive cells in each line represents p53-dependent transcription, we examined the clone VRs.2, in which high levels of dominant-negative mutant p53 are expressed (Figure 2a We next examined the induction of p53-dependent transcription by u.v. irradiation in these lines. A dose of 10 Jm 72 was used as higher doses resulted in excessive cell death in Vh1 derived lines. Marked induction of b-galactosidase expression occurred in over 50% of VRn.6 cells within 9 h of irradiation ( Figure 1h , Tables 1 and 2) accompanied by a twofold increase in p53 protein levels within 4 h (Figure 3a) . b-galactosidase induction was slower in FRn.4 cells, but comparable levels were reached at 24 h, by which point p53 protein had increased by at least sixfold. There was no signi®cant induction in VRs.2 cells at 378C by 9 h (Figure 2d , Tables 1 and 2) or 24 h (not shown) post-irradiation, demonstrating that the induction of reporter gene expression by u.v. was p53-dependent. (Figure 3b ). The p53CON oligonucleotide was used as p53 binds to this with higher anity compared to the RGC consensus in this assay (ElDeiry et al., 1992) . We also obtained essentially similar results with the p53-consensus from the human WAF-1 gene.
Figure 1 p53 protein expression and p53-dependent transcription in VRn.6 and FRn.4 cells. p53 protein levels were determined by immunocytochemistry with pAb421 (a,c,e,g) (the anti-p53 polyclonal antibody, CM1, gave similar results). p53-dependent transcription was demonstrated by X-gal enzyme histochemistry (b,d,f,h) (cells are counter-stained with haematoxylin). FRn.4 (a,b,e,f) and VRn.6 (c, d, g, h) were examined either unirradiated (a,b,c,d) or 24 h following exposure to 10 Jm 72 UV-C (e,f,g,h). Note that in irradiated FRn.4 cells, in addition to scattered, strongly staining cells, there was a low magnitude, increase in p53 expression in the majority of the cell population `Active' p53 protein which was constitutively able to bind to the consensus sequence (without irradiation) was found to be at a similarly low level in both VRn.6 and FRn.4 cells, corresponding to the low levels of p53-dependent transcription observed in both cell lines. Thus the failure of the excess wild-type p53 protein in VRn.6 cells to induce sequence-speci®c transcription appears to be due to its lack of sequence-speci®c DNA binding. Following u.v. irradiation an increase in binding to the oligonucleotide was observed in both lines with kinetics initially consistent with the induction of reporter expression. The subsequent fall in binding in VRn.6 extracts to near basal levels by 20 h in contrast to sustained levels of b-galactosidase activity can be explained by the stability of the bacterial b-galactosidase protein.
The pAb421 antibody has been previously shown to bind a C-terminal negative regulatory domain of p53. In addition to binding the`active' form of p53, resulting in a super-shift on the EMSA gel, it can also bind a`latent' form of p53 and activate it for DNA binding (Hupp et al., 1992) . Addition of this antibody to the gel-shift assays revealed a large pool of latent p53 protein in extracts from VRn.6 cells, both before and after irradiation. Latent p53 was also demonstrable in FRn.4 cells following u.v. irradiation.
This assay does not determine whether all of the excess wild-type p53 in unirradiated VRn.6 cells is in à latent' form, or whether a further pool of p53 is present which is unable to bind the DNA consensus, even in the presence of pAb421. However comparison of unirradiated VRn.6 cells with FRn.4 at 4 h postirradiation ( Figure 3a and b) showed that VRn.6 extracts contained *threefold greater levels both of pAb421-activatable and of total p53 protein. This equivalence indicates that there is no preferential accumulation of a signi®cant`inactivatable' pool of p53 in VRn.6 cells.
p53-dependent mdm-2 expression in Vh1 cells
To complement the results obtained from the reporter assays we also examined the expression of the endogenous p53 responsive genes, mdm-2 and WAF-1, in a panel of previously derived Vh1 derivative lines (Figure 4a ). WAF-1 mRNA was readily detectable in control Vh1.neo clones in the absence of any exogenous DNA damaging agent. However, levels were not signi®cantly reduced in clones expressing either dominant-negative p53 (SCX) or SV40 T, indicating that the DNA damage-independent expression of WAF-1 in the Vh1.neo cells is not due to p53.
In contrast, mdm-2 mRNA was detected in Vh1.neo cells, but not in the Vh1.SCX or SV40 T clones. Thus mdm-2 is expressed in Vh1 cells due, at least in part, to the presence of active wild-type p53 protein. We have previously demonstrated similar mdm-2 expression in the parent Vh1 line, in addition to all the other similarly derived PRT.ras.V lines (not shown). Mdm-2 mRNA levels in FRTL-5 cells were below the limit of detection. The mdm-2 gene was found, by Southern blotting, not to be ampli®ed in the PRT.ras.V lines in comparison to normal rat liver DNA (not shown). Investigation of mdm-2 protein expression by Western blotting of nuclear extracts (Figure 4b ) demonstrated expression of 90, 58 and 54 kD species in VRn.6 cells, whereas mdm-2 was barely detectable in FRn.4 extracts. Surprisingly, irradiation of VRn.6 cells with 10 Jm
72
UV-C consistently resulted in a dramatic reduction in mdm-2 protein levels by 4 h, followed by an increase to above normal by the 20 h time point. Only a very slight increase in mdm-2 protein expression was seen in FRn.4 cells following u.v. irradiation. Northern blotting (Figure 4c ) determined that the repression of mdm-2 expression by u.v. in VRn.6 cells occurred at the RNA level. In contrast, exposure to the radiomimetic drug, bleomycin, resulted only in an increase in mdm-2 expression, consistent with an activation of p53-dependent transcription by this agent. A small fraction of the p53 protein in Vh1 cells is complexed to mdm-2
As mdm-2 binds amino acids 18 ± 23 at the N terminus of p53 and inhibits its sequence-speci®c DNA binding activity (Chen et al., 1993; Picksley et al., 1994) , we next determined whether nuclear extracts of VRn.6 cells contain p53-mdm-2 complexes. Immunoprecipitation ( Figure 5 ) with antibody SMP14 speci®c to the central region of mdm-2 (a.a. 154 ± 167) co-precipitated p53, but this accounted for only *2.5% of the total p53 that could be precipitated by the p53-speci®c antibody pAb421. This was not due to limiting levels of mdm-2 since, in the reciprocal analysis, pAb421 precipitated less than 10% of the total mdm-2 precipitatable by SMP14.
Activation of p53-dependent transcription by microinjection of antibodies to p53 and mdm-2
Microinjection of pAb421 has been shown to activate the latent p53 in NIH3T3 cells (Hupp et al., 1995) and, consistent with these ®ndings, pAb421 induced an increase in the proportion of X-gal positive VRn.6 cells from 1.6% to 14.3% 24 h after injection (Table 3) Figure 5 p53-mdm-2 interactions. Nuclear extracts from unirradiated VRn.6 (250 mg protein) or VRs.2 (40 mg protein) cells were immunoprecipitated with antibodies to mdm-2 (SMP14), p53 (pAb421) or SV40 T (pAb419, irrelevant control) and the blot probed for p53 (CM1 polyclonal antibody) then reprobed for mdm-2 (SMP14). VRs.2 cells express higher levels of both p53 and mdm-2, and so less total protein was precipitated to facilitate comparison between the two cell lines. Only the 90 kD mdm-2 protein is shown as the 54/58 kD bands were masked by mouse IgG heavy chain. Precipitation with pAb421 and SMP14 demonstrates that only a small fraction of the p53 and mdm-2 in the extracts are in complex with each other in VRn.6 extracts (*2.5% of the p53). This is unlikely to be due to dissociation of complexes during extraction as in extracts from VRs.2 cells shifted to 32.58C *25% of the p53 is precipitated by SMP14 Cells were ®xed 24 h after microinjection and incubated with the Xgal substrate for 20 h. Injected cells were then identi®ed by immunocytochemistry for rat and mouse immunoglobulins, and the percentage of b-galactosidase positive cells determined. Results shown are mean+s.e.m. for three separate experiments. Note that injection of VRn.6 cells with 0.2 mg/ml pAb421 produced a similar response to 2 mg/ml (not shown), suggesting that the relatively small induction of b-galactosidase observed was not due to limiting antibody concentration mdm-2 regulates p53 in transformed epithelial cells JP Blaydes et al increase was observed within 9 h), though the intensity of staining was faint (Figure 6d ). pAb421 was without observable eect in FRn.4 cells (Figure 6a , Table 3 ).
In contrast, when VRn.6 cells were injected with antibody 3G5, which recognises an epitope in the p53-binding domain of mdm-2 (a.a. 59 ± 89) (Chen et al., 1993) , intense X-gal staining was obtained in 66% of injected cells (Figure 6e ). As this staining masked the immunocytochemical detection of IgG in injected cells, in one experiment incubation in X-gal substrate was limited to 1 h to con®rm that the induction was exclusive to injected cells (not shown). The induction of b-galactosidase by 3G5 was p53 dependent as the response was negligible in VRs.2 cells (Figure 6g ). (The slight response seen was most likely a consequence of the unavoidable cooling of dishes during microinjection leading to activation of the temperature sensitive ala 143 p53). 3G5 microinjection also caused a marked increase in b-galactosidase activity in FRn.4 cells, but in a much smaller proportion (15%) ( Figure  6b ). Intermediate intensity staining was rarely observed in either VRn.6 or FRn.4 cells injected with this antibody.
Discussion
The primary aim of this study was to determine the mechanism whereby some transformed cells, including a signi®cant proportion of certain common human tumours, are able to tolerate expression of high levels of endogenous wild-type p53 protein. As a model system we used the Vh1 cell line, which was derived from an in vitro model of thyroid epithelial tumorigenesis in which the appearance of high levels of wild-type p53 protein is associated with an, as yet uncharacterised, spontaneous immortalisation event (Burns et al., 1992a; Blaydes et al., 1995). We ®rst wished to determine whether the lack of observable biological eect (i.e. growth arrest or apoptosis) of the high levels of p53 in Vh1 cells was due to inactivity of the p53 protein itself, or a defect in a downstream signalling pathway. Our results using cells stably transfected with pRGCDfos-lacZ clearly demonstrate that the high levels of wild-type p53 protein present in the Vh1 cell line are not accompanied by a corresponding increase in p53-dependent transcription of the reporter construct, or of an endogenous target gene, WAF-1. This ®nding that the`excess' wild-type p53 in Vh1 cells is largely inactive as a sequence-speci®c activator of transcription is consistent with recent studies of keratinocytes (Weinberg et al., 1995) and F9 teratocarcinoma cells (Lutzker and Levine, 1996) which also express high levels of wild-type p53.
Having ascertained that the excess wild-type p53 in Vh1 cells is not functional as a transcriptional activator, we next examined the basis for this lack of activity. u.v. irradiation of Vh1 cells showed that the p53 pathway in these cells can be activated, given the appropriate stimuli, in contrast to the situation in cells in which p53 is inactivated by, for example, overexpression of mutant p53 Kuerbitz et al., 1992) or SV40 T (Mietz et al., 1992) . At least two mechanisms could therefore explain the p53 phenotype in unirradiated Vh1 cells: either (i) the excess p53 is incompletely activated, or (ii) it is inhibited by low levels of a competitive inhibitor.
EMSA analysis initially suggested the ®rst mechanism, in that the majority of the p53 protein was present in a latent form which could be activated to bind DNA in vitro by interaction of the pAb421 antibody with the C-terminal inhibitory domain. The presence of latent p53 in the cells was further supported by the induction of p53-dependent reporter transcription following microinjection of pAb421 antibody, although this response was weaker than expected.
Latent p53, however, is detectable in physiologically normal, untransformed cells (Hupp et al., 1995) and furthermore represented a high proportion of the total p53 protein in irradiated FRTL-5 cells which were clearly exhibiting a major p53-dependent transcriptional response. This suggests that the presence of latent p53 may not, in itself, indicate any abnormality in p53 function, but is merely an inevitable consequence of activation of the p53 pathway, whether by irradiation or, in the case of Vh1 cells, by some feature of the transformed state. We were therefore led to consider additional mechanism(s) to account for the tolerance of wild-type p53 in these cells.
A clue came from the analysis of the expression of endogenous p53 target genes, which revealed that Vh1 cells express high levels of mdm-2 mRNA and protein relative to FRTL-5 cells, and that this expression is, at least in part, p53 dependent. This was in contrast to the lack of any signi®cant, detectable elevation of p53-dependent transcription of the WAF-1 gene, or of the stably integrated pRGCDfos-lacZ reporter.
Mdm-2 binds to an N terminal region of p53 (Chen et al., 1993; Picksley et al., 1994) , inhibiting its transcriptional activation function (Momand et al.. 1992) and has thus been proposed to regulate p53 by a negative-feedback-loop mechanism (Wu et al., 1993) . Immunoprecipitation analysis con®rmed that p53-mdm2 complexes were present in Vh1 cells, but, despite the high levels of mdm-2 expression, involved only a very small proportion of each protein. This is consistent with reports in other cell types (Finlay, 1993; Otto and Deppert, 1993; Perry et al., 1993; Momand and Zambetti, 1996) and incidentally explains why the high mdm-2 levels in Vh1 cells did not cause a signi®cant inhibition of pAb421-activatable DNAbinding in the EMSA experiment. It is not known why only a subset of mdm-2 and p53 protein molecules appear to form a tight interaction. It is unlikely that mdm-2 selectively recognises p53 in an active, DNA binding, conformation as it binds equally well to mutant and wild-type proteins . Oligomerisation of p53 is known to be required for mdm-2 binding (Marston et al., 1995) and there is evidence indicating that phosphorylation of sites in the N terminus of p53 may also regulate the interaction (Picksley et al., 1994) .
In order to determine whether the small amount of p53 bound to mdm-2 in Vh1 cells was biologically signi®cant, the eect on p53 function of disrupting this interaction was examined. This was achieved by microinjection of an antibody, 3G5, directed against the p53-binding domain of mdm-2. Whilst this antibody does not dissociate pre-formed p53-mdm-2 complexes in vitro (Chen et al., 1993) , the mdm-2 protein has a short half-life Finlay, 1993) , and we considered it likely that it would prevent the formation of new p53-mdm-2 complexes, analogous to the ability of the anti-p53 antibody Bp53-19 to block the binding of mdm-2 to a p53-derived peptide in vitro (Picksley et al., 1994) . 3G5 caused a dramatic increase in p53-dependent transcription in the majority of Vh1 cells injected (as well as in 15% of FRTL-5 cells). Interestingly, in view of the small proportion of p53 bound to mdm-2 in comparison to the high levels of latent (pAb421 activatable) p53 in the cell extracts, this response was of much greater magnitude than that obtained following microinjection with pAb421. Possible explanations for this include: (i) that activation of latent p53 for transcriptional activation may require events additional to the activation of DNA-binding, (ii) that pAb421 binding may have some inhibitory steric eects, or, perhaps most likely, (iii) that the response may be`dampened' by the resulting stimulation of the mdm-2 negative-feedback-loop (which of course cannot reduce the response to 3G5).
We cannot formally exclude the possibility that activation of p53 by 3G5 could have been an indirect consequence of its inhibiting a function of mdm-2 other than binding to p53. This is unlikely, however, since blockade of the currently known p53-independent functions of mdm-2 (inhibition of the growth regulatory function of Rb (Xiao et al., 1995) and activation of E2F activity (Martin et al., 1995) ) would be predicted to have the opposite eect on p53 activity.
On the reasonable assumption that the eect of 3G5 is through disruption of mdm-2-p53 complexes, our result provides further support for the view (Finlay, 1993 ) that mdm-2 selectively binds a small pool of p53 that would otherwise be active. The identi®cation of dierences between mdm-2-bound and free p53 is thus potentially an area of major importance.
An interesting, incidental, observation from our experiments was that 10 Jm 72 UV-C irradiation mdm-2 regulates p53 in transformed epithelial cells JP Blaydes et al induced a rapid downregulation of mdm-2 expression in Vh1 cells, and failed to induce its expression in FRTL-5 cells, despite high levels of p53-dependent transcription. The mechanism for this is unclear, but is not restricted to this cell type as high u.v. doses have previously been shown to delay the induction of mdm-2 expression in murine C127 cells (Perry et al., 1993) , and u.v. fails to induce mdm-2 expression in murine keratinocytes in vivo (Burden et al., 1996) . Thus repression of mdm-2 expression may contribute to the reportedly higher ecacy of u.v. in inducing p53 dependent transcription compared to ionising radiation (Lu and Lane, 1993; Zhan et al., 1993) .
Taken together, our data suggest a model for tolerance of wild-type p53 in Vh1 cells in which the key feature is that transcription of mdm-2 shows a much greater sensitivity to stimulation by active p53, compared to that of other p53-responsive genes. Therefore, even when the p53 pathway is activated by the transformed state, an equilibrium can be reached at which the mdm-2 feedback-loop can be suciently upregulated by levels of free, active p53 which are too low to signi®cantly activate the transcription of eectors of growth arrest and apoptosis such as WAF-1. This dierential sensitivity presumably depends partly on dierences in the respective p53-responsive regions of the genes (El-Deiry et al., 1993; Juven et al., 1993; Wu et al., 1993 ) (though we did not detect any increase in`active' p53 binding to a 30 bp mdm-2 consensus oligonucleotide in Vh1 cells), and partly on regulatory co-factors which either bind p53 itself, or interact with other regions of the mdm-2 promoter. We suggest that this apparent hypersensitivity of the mdm-2 autoregulatory feedback-loop is at least partly cell-type speci®c, and predict that it will occur in those cell types that give rise to tumours able to tolerate overexpression of wild-type p53. Candidates currently include well-dierentiated thyroid carcinomas (Donghi et al., 1993) , testicular cancers (Riou et al., 1995) and a signi®cant proportion of breast cancers (Dunn et al., 1993; Cornelis et al., 1994) .
It has already been proposed that small molecules designed to disrupt p53-mdm-2 interactions may provide a rational therapy for the treatment of tumours in which the mdm-2 gene is ampli®ed (Oliner et al., 1993; Picksley et al., 1994) or otherwise overexpressed (Picksley et al., 1996) . Our results greatly support this prospect, and extend its potential to a wide range of cancers which express high levels of wild-type p53. Cell lines such as those described here should provide useful models for developing such agents designed to disrupt p53-mdm-2 interactions.
Materials and methods

Cell culture
FRTL-5 is a non-transformed, well dierentiated, cell line derived following the rare spontaneous immortalisation of primary rat thyroid epithelial cells (Ambesi-Impiombato et al., 1980) . The SB5 subclone (Burns et al., 1992b) was used in this study. Cells were cultured in`2 : 1 : 1 medium', consisting of Dulbecco's Modi®ed Eagle's Medium (Gibco BRL), Ham's F12 (Flow) and MCDB 104 (Gibco BRL) (2 : 1 : 1 by volume), supplemented with 5% calf serum (CS, Gibco BRL), 2.5 mU/ml TSH, 45 mg/ml ascorbic acid, 10 mg/ml insulin (all from Sigma), 5 mg/ml transferrin and 10 78 M hydrocortisone (both from Calbiochem/Novabiochem). PRT.ras.Vh1 (Vh1) cells have been described previously (Blaydes et al., 1995) and were cultured in 2 : 1 : 1/5% CS. Both Vh1 (Blaydes et al., 1995) and FRTL-5 cells (Blaydes, unpublished data) express only wild-type p53 as determined by sequencing of PCR ampli®ed cDNA. The Vh1.SCX subclones stably expressing human ala 143 mutant p53 and the Vh1.neo control clones have been described previously (Blaydes et al., 1995) . Vh1.SV40 T was derived following infection of Vh1 cells with the pSVU-19.5 retroviral vector (Jat and Sharp, 1986) which confers expression of SV40 T.
Immunocytochemistry for p53
Cell monolayers were ®xed in acetone : methanol (1 : 1) for 10 min at 7208C. p53 protein was detected by a standard indirect immunoperoxidase procedure using pAb421 (Harlow et al., 1981) followed by peroxidase-labelled rabbit anti-mouse immunoglobulin (Dako) as secondary antibody and a diaminobenzidine (DAB) hydrogen peroxide substrate.
DNA transfection
Cells growing in 90 mm dishes were transfected by strontium phosphate co-precipitation (Brash et al., 1987) . 20 mg of the p53 dependent reporter plasmid pRGCDfoslacZ or pDfos-lacZ control vector (Frebourg et al., 1992) (a gift from S Friend) was co-transfected with 2 mg of either pSV 2 neo (Southern and Berg, 1982) or pC53-SCX3 (Baker et al., 1990) , which encodes the temperature sensitive ala 143 mutant of human p53 (Zhang et al., 1994) and the neo gene. Two days after transfection cells were passaged into selective medium containing 0.4 mg/ml G418 (Gibco/BRL). G418 resistant colonies were isolated by ring cloning, expanded, and examined for p53 dependent expression of the reporter construct. To determine the copy number of the tranfected pRGCDfoslacZ plasmid, genomic DNA extracted from transfected clones was digested with either BamHI or HindIII, electrophoresed on a 1% agarose gel, blotted and probed for bacterial b-galactosidase DNA using standard techniques (Sambrook et al., 1989) .
Analysis of p53-dependent transcriptional activity
b-galactosidase activity in individual cells was determined by X-gal enzyme-histochemistry. Cells were ®xed in 0.5% glutaraldehyde (in PBS) for 15 min, washed for 15 min in 0.02% NP40, 0.01% sodium deoxycholate, 2 mM MgCl 2 in PBS, then incubated at 378C for 20 h in this solution plus 5 mM potassium ferricyanide, 5 mM ferrocyanide and 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal). Cells were counter-stained with haematoxylin and mounted in DPX.
For assessment of total b-galactosidase activity, a colorimetric assay was used (Sambrook et al., 1989) . Brie¯y, cells in 90 mm dishes were washed in PBS, scraped o, pelleted by centrifugation and resuspended in 100 ml 0.25 M Tris (pH 7.5). Cells were lysed by three cycles of freeze-thaw, debris removed by centrifugation, and protein concentration determined (Bio-Rad). 25 mg total protein (in 50 ml 0.25 M Tris) was mixed in microtitre plates with 50 ml 26 assay buer containing 1.33 mg/ml o-nitro-phenyl-b-Dgalactopyranoside (Sigma) and incubated at 378C for 30 min. The reaction was stopped by the addition of 150 ml NaCO 3 , absorbance read at 420 nm, and b-galactosidase activity calculated from a standard curve of recombinant bgalactosidase (Sigma).
DNA damaging agents
Cells were washed, the medium removed, and dishes placed under a San Gabriel, CA) . UV-C exposure (254 nm) was at a rate of 1 Jm 72 s 71 . The cells were then refed with complete medium. Bleomycin (Lundbeck, Milton Keynes, UK) was prepared as a 7.5 mg/ml stock solution in H 2 O and added to the medium at a ®nal concentration of 250 mg/ml. After 1 h the medium was removed, cells washed and fresh medium added.
Northern blotting
Total RNA was extracted using RNAzol B (AMS Biotechnology). 25 mg RNA was loaded per lane, electrophoresed through a 1% agarose-glyoxal gel (Sambrook et al., 1989 ) and transferred to Hybond N + membranes (Amersham) by capillary blotting. Filters were probed with 32 P-labelled DNA (Rediprime, Amersham) derived from the following plasmids; MDMFL4 encoding human mdm-2 cDNA (Oliner et al., 1992 ) (a gift from K Kinzler), p21-9C encoding mouse WAF-1 cDNA (Huppi et al., 1994) (a gift from K Huppi), pHcGAP encoding human glyceraldehyde 3-phosphate dehydrogenase cDNA. Filters were washed at low stringency (0.1% SDS, 16SSPE, 658C) and bands visualised by autoradiography.
Electrophoretic mobility shift assay (EMSA) for p53 sequencespeci®c DNA binding Seventy to eighty percent con¯uent cell monolayers in 150 mm dishes were washed in PBS then incubated for 15 min on ice in buer A (20 mM HEPES pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.1% NP40, 1 mM DTT and protease inhibitors). Cells were scraped o in a total of 1 ml buer A and incubated for a further 15 min before being pelleted at 1000 g (4 min) then resuspended in 100 ± 200 ml buer B (buer A plus 0.5 M NaCl). Debris was removed by centrifugation at 15 000 g (15 min, 48C), aliquots were snap frozen and stored at 7808C until required. Protein concentration was determined using a Coomassie Plus assay (Pierce). For EMSA analysis 8 mg protein was added to a binding reaction containing 200 ng herring sperm DNA, 0.3 mg/ml BSA, 3 mM DTT in a total volume of 28 ml buer A (®nal NaCl concentration 75 mM). 100 ng pAb421 (Oncogene Science) was added where indicated. After 10 min at 208C *0.25 ng of end-labelled p53CON double stranded oligonucleotide (GGACATGCCCGGGCATGTCC) (Funk et al., 1992) was added and the samples incubated a further 30 min at 208C. 1 ml bromophenol blue was added to samples before loading on a 4% acrylamide/0.56 TBE/ 0.1% Triton X-100 gel. Electrophoresis in 0.56 TBE/0.1% Triton running buer was at 250 V for 2.5 h at 48C. The gel was ®xed, dried and exposed to ®lm for 1 ± 3 days.
Western blotting and immunoprecipitation
For Western blotting of nuclear extracts (prepared as for EMSA analysis), equal amounts of protein (40 mg) were boiled in Laemmli buer and electrophoresed on a 10% SDS-acrylamide gel. Proteins were transferred onto Transblot membrane (Bio-Rad) and, following blocking in 10% milk, 0.2% Tween 20 in PBS, probed with either CM1 (anity puri®ed rabbit polyclonal anti-human p53 , a gift from D Lane) or SMP14 (mouse monoclonal anti-human mdm-2 (Picksley et al., 1994) (Santa Cruz Biotechnology)), diluted in 1% BSA, 0.2% Tween 20 in PBS. Detection was with an ECL kit (Amersham), using the appropriate secondary antibody.
For immunoprecipitation 40 ± 200 mg of nuclear extract protein was mixed with 1 mg puri®ed antibody (or 40 ml of hybridoma supernatant) and 10 ml of protein G-sepharose beads (Sigma) in a total volume of 200 ml NETS buer (50 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% NP40, protease inhibitors). Samples were incubated at 48C for 18 h with head to head tumbling. The beads were then pelleted and washed three times with NETS buer before boiling in Laemmli buer and loading onto the gel. Antibodies used for immunoprecipitation were SMP14, pAb421 and pAb419.
Microinjection
Cells were plated in 60 mm dishes 24 h prior to microinjection. Media was replaced with Leibovitz's L-15 medium containing serum to control the pH during microinjection, which was performed with an Eppendorf microinjection system (Microinjector 5242, Micromanipulator 5170; Carl Zeiss, Oberkochen), mounted on an Axiovert 35M microscope with heated stage. Puri®ed mouse monoclonal antibodies pAb421 (Oncogene Science), 3G5 (Chen et al., 1993) (puri®ed from hybridoma supernatant, kindly supplied by AJ Levine, using protein A-sepharose), and anity puri®ed mouse immunoglobulin G (control) (Southern Biotechnology) were injected at a concentration of 2 mg/ml in phosphate buered saline pH 7.4. Anity puri®ed rat IgG (Southern Biotechnology) was co-injected (at a concentration of 3 mg/ml) to increase the amount of IgG available for subsequent immunocytochemical detection. Immunoglobulins were injected (1 to 10¯) into the cell nuclei and approximately 200 ± 300 cells were injected in a typical experiment.
Following microinjection, fresh medium was added and the cells incubated for 24 h before being ®xed and X-gal histochemistry performed. Injected cells were identi®ed by immunoperoxidase staining using a mixture of horseradishperoxidase conjugated goat anti-rat and anti-mouse IgG (Dako). Cells were mounted in Mowiol (Calbiochem) and the percentage of injected cells which were b-galactosidase positive determined.
